scout
Opinion|Videos|December 6, 2023

Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

Thomas C. Krivak, MD, shares the positive results from the RUBY trial of pembrolizumab plus chemotherapy followed by maintenance in patients with dMMR advanced endometrial cancer, supporting its approval and use in this population.

Episodes in this series

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME